<DOC>
	<DOCNO>NCT01281631</DOCNO>
	<brief_summary>This Phase 2 randomize , double-blind , placebo-controlled , multicenter study NP001 subject ALS .</brief_summary>
	<brief_title>A Study NP001 Subjects With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study NP001 subject ALS conduct multiple center . Drug placebo give intravenously . Approximately 105 subject enrol . Subjects allocate ( 1:1:1 ) placebo 2 dose level NP001 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Subjects sporadic familial ALS classify definite , probable , laboratorysupported probable ALS accord revise El Escorial criterion . A list key criterion list : Onset symptom less 3 year prior study entry . Forced Vital Capacity ( FVC ) least 70 % predict age height . Stable dose riluzole undergoing treatment agent . For female : Not childbearing potential agree use adequate birth control study . Unstable medical condition ( ) ALS . Life expectancy le 6 month . Require lifesustaining intervention 6 month follow randomization . Have tracheotomy use ventilatory assistance [ include Bilevel Positive Airway Pressure ( BiPAP ) Continuous Positive Airway Pressure ( CPAP ) ] . Active pulmonary disease . Immune modulator therapy within 12 week study entry participation study agent within last 4 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ALS</keyword>
</DOC>